Latest news on COVID-19 and PIDs

IPOPI is committed to monitor closely the COVID-19 pandemic and to share evidence-based and expert validated information to the global primary immunodeficiency (PID) patients community and to our stakeholders.

The situation is evolving rapidly all over the world with new restrictions being imposed in an increasing number of countries. Our priority is the safety of all PID patients and the safety of supply of their life-saving treatments both during and after the COVID-19 pandemic. IPOPI has been engaging on several fronts to fast track the publication of statements, answer frequently asked questions and participate in international efforts to collect data on COVID-19 in PIDs.

This page aggregates all of IPOPI’s efforts and selected external statements.

COVID-19 Statements

IPOPI commits to publish and update its statements as the situation evolves. Please always refer to the latest statement which contains up to date recommendations.

October 28, 2021 5th Update

Joint statement

The fifth update of the Joint statement offers information on COVID-19 in PID patients including vaccinations, treatments and much more.

English

November 27, 2020 4th Update

Joint statement

The forth update of the Joint Statement offers a general update, the latest on treatments as well as new information on COVID-19 in PID patients.

English Spanish

May 28, 2020 3rd Update

Joint statement

The third update of the Joint Statement, includes a general update, details on paediatric inflammatory multisystem syndrome, COVID-19 tests and more.

English Slovenian

April 08, 2020 2nd Update

Joint statement

The second update of the Joint Statement, now also in partnership with IUIS, includes a general update, new details on treatments, clinical trials of prospect medicines and ongoing medical surveys.

English Slovenian

March 11, 2020 1st Update

Joint statement

IPOPI published a Joint Statement together with ESID, INGID, APSID, ARAPID, ASID, CIS, LASID and SEAPID on the COVID-19 epidemics. Covers general and PID specific precautions and advises monitoring regional public advices.

English Arabic Dutch French Polish Russian Spanish

12 February 2020

IPOPI Statement

English Arabic

Recommendations: Monoclonal antibodies, Vaccination for PID patients

4 November, 2021

Joint IPOPI-ESID statement

Recommendation on the use of monoclonal antibody treatment for patients with PID in the context of the COVID-19 pandemic

English

29 January, 2021

Recommendation on vaccination against SARS-COV-2 for patients with PID

This statement gathers the latest information concerning the current vaccination programmes against SARS-CoV-2, the causative agent of COVID-19. IPOPI will revise and update these recommendations as new evidence is compiled and analysed

English Arabic Greek Spanish

COVID-19 and PIDs FAQs

2 November 2021

IPOPI has gathered the most pressing COVID-19 and PIDs questions received from our National Member Organisations (NMOs) into a FAQs page. Stay tuned for further updates!

COVID-19 Learning Expedition Report released

January 12, 2021

IPOPI launched the COVID-19 Learning Expedition (LEX) in July 2020, to identify, analyse and provide recommendations on issues brought about by the COVID-19 pandemic for patients with primary immunodeficiency (PID).

English

Policy Actions

13 May, 2020

IPOPI letter to the APEC Blood Policy Forum

IPOPI sent a letter to the APEC Bloof and Policy Forum representatives highlighting the importance of ensuring blood/plasma/PDMP supply during current COVID-19

Open Letter

March, 2020

IPOPI calls on authorities to ensure appropriate supply of immunoglobulins

IPOPI just published an Open Letter calling international, regional and national authorities to ensuring sufficient blood and plasma supply during and after the COVID-19 outbreak.

Open Letter

April 09, 2020

APLUS Letter on Masks Provision to Source Plasma and Blood Collection Facilities to Ensure Supply of Life-Saving Treatments

Read the letter to the US Department of Health and Human Services

14 April, 2020

Open letter from PLUS to EU Ministers of Health

Read the Open Letter

20 April, 2020

PLUS Statement on Access to Plasma Derived Medicinal Products & home care during the COVID-19 pandemic

Read the Statement

Article

Global Survey on COVID-19 and PIDs (for physicians)

IPOPI is participating in the launch of a global survey on COVID-19 and PIDs, working jointly with International Union of Immunological Societies (IUIS) and other medical societies.

The survey is now entering phase 2 – please help us by sharing it with national medical advisers and all national doctors who you know are managing PID patients in your country:

COVID-19 and PID survey

External materials

Please find external helpful resources and updated information on the COVID-19 outbreak.

The Plasma Protein Therapeutic Association (PPTA) has issued statements and information regarding the safety and supply of plasma derived medicinal products including immunoglobulins.
The World Health Organisation (WHO) regularly publishes updates and new recommendations
WHO Newsroom // Detailed Q&As
The European Centre for Disease Control (ECDC) regularly posts updates and offers a COVID-19 dedicated webpage
The US CDC also offers resources and information
COVIBOOK – COVID 19 explained to children (in 17 languages)

Improving PID patients’ lives. Worldwide.